Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Masimo Corporation - Common Stock (NQ:MASI)

147.09 +2.84 (+1.97%)
Streaming Delayed Price Updated: 10:00 AM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Masimo Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Masimo to Present in the BofA Securities 2025 Health Care Conference
From Masimo
Via Business Wire
Masimo’s (NASDAQ:MASI) Q1: Beats On Revenue But Stock Drops
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 24.5% year on year to $372 million. The company expects the full... 
Via StockStory
Masimo to Sell Consumer Audio Business to HARMAN International
From Masimo
Via Business Wire
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Masimo's Earnings: A Preview
 
Via Benzinga
Is the Market Bullish or Bearish on Masimo?
 
Via Benzinga
Masimo Reports First Quarter 2025 Results
From Masimo Corporation
Via Business Wire
Masimo (MASI) Q1 Earnings Report Preview: What To Look For
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after market close. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6
From Masimo
Via Business Wire
$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
Masimo Makes A Bullish Post-Earnings Move. Why One Analyst Is Cautious.
Future earnings growth could falter as Masimo makes steep cost reductions. 
Via Investor's Business Daily
3 Healthcare Stocks Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
Intuitive Surgical Gets Rating Upgrade. No. 1 In Its Industry; Profits, Sales Climbing.
Intuitive Surgical, No. 1 stock in its group, has a deep moat around its technology and has sold is robotic surgical systems for 30 years. 
Via Investor's Business Daily
Topics Initial Public Offering
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference
From Masimo
Via Business Wire
How Is The Market Feeling About Masimo?
 
Via Benzinga
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Masimo (MASI): Buy, Sell, or Hold Post Q4 Earnings?
What a fantastic six months it’s been for Masimo. Shares of the company have skyrocketed 45.8%, hitting $167.70. This was partly due to its solid quarterly results, and the run-up might have investors... 
Via StockStory
3 Small-Cap Stocks in Hot Water
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
Xpeng, Li Auto And Nutanix Are Among Top 12 Large-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?
These large-cap stocks were top performers last week. Heico, Xpeng, Li Auto, Lineage, Erie Indemnity, Lloyds, Unum, FICO, Masimo, Smith & Nephew, AB InBev, and Nutanix all saw significant gains. 
Via Benzinga
Masimo to Present in the 46th Annual Raymond James Institutional Investor Conference
From Masimo
Via Business Wire
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
Why Is Masimo (MASI) Stock Soaring Today
Shares of medical tech company Masimo (NASDAQ:MASI) jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS... 
Via StockStory
Masimo Tops EPS, Revenue Expectations
Masimo impressed with a robust earnings report driven by its healthcare segment, despite challenges from non-healthcare operations. 
Via The Motley Fool
Masimo (NASDAQ:MASI) Posts Better-Than-Expected Sales In Q4
Medical tech company Masimo (NASDAQ:MASI) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.4% year on year to $600.7 million. Its non-GAAP profit of $1.80 per share... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.